Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Catherine Kendall Major, Hagop Kantarjian, Koji Sasaki, Gautam Borthakur, Tapan Kadia, Naveen Pemmaraju, Courtney DiNardo, Nicholas J. Short, Naval Daver, Elias Jabbour, Richard Champlin, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Steven Kornblau, William Wierda, Sherry Pierce, Farhad Ravandi, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Acute myeloid leukemia (AML) carries poor survival and high recurrence rate. We conducted a retrospective analysis of AML patients (N = 453) treated with chemotherapy only or chemotherapy + hematopoietic cell transplant (HCT) who maintained their first complete remission (CR) for ≥3 years. Prior comorbidities, new comorbidities, secondary malignancies, late relapse, and causes of death (COD) were documented. New comorbidities for chemotherapy only patients (n = 304) included renal disease (10%), and osteopenia/osteoporosis (38%) for HCT patients (n = 149). Incidence of hypertension was similar in the chemotherapy only cohort and chemotherapy + HCT cohort (14% vs 17%). Secondary malignancies occurred in 13%, commonly skin, prostate and breast cancers. Common COD included: secondary malignancy (4%), HCT complications (3%), and late relapses (5%). Overall, 12% had a late relapse. Median overall survival for chemotherapy only and HCT was 10.7 and 12.7 years, respectively. Long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2020

Keywords

  • Acute myeloid leukemia
  • comorbidities
  • remission
  • survivorship

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years'. Together they form a unique fingerprint.

  • Cite this

    Major, C. K., Kantarjian, H., Sasaki, K., Borthakur, G., Kadia, T., Pemmaraju, N., DiNardo, C., Short, N. J., Daver, N., Jabbour, E., Champlin, R., Garcia-Manero, G., Konopleva, M., Andreeff, M., Kornblau, S., Wierda, W., Pierce, S., Ravandi, F., & Cortes, J. (Accepted/In press). Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2020.1802450